Foravirumab is a monoclonal antibody for the prophylaxis of rabies.[1] It is under development by Sanofi/Crucell.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | rabies virus glycoprotein |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6400H9914N1718O1998S44 |
| Molar mass | 144304.38 g·mol−1 |
  (what is this?) (verify) | |
References
edit- ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
- ^ Khardori NM (2011). Biologic Response Modifiers in Infectious Diseases, An Issue of Infectious Disease Clinics. London: Elsevier Health Sciences. p. 158. ISBN 978-1-4557-1207-6.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |